714 results about "Erythroid cell" patented technology

The present invention provides a process for the production of erythropoietin (EPO) with high purity and with a desired profile of EPO glycol-isoforms by using a combination of specific chromatographic steps in such a manner that the starting EPO glycol-isoform profile is changed or modified. The applied chromatographic steps includes at least (a) dye affinity chromatography, and (b) hydrophobic chromatography and/or (c) anion-exchange chromatography. In a preferred embodiment, the process further includes (d) gel filtration chromatography. The present invention also provides a process for the determination of erythropoietin (EPO) glycol-isoform profile in an EPO containing composition.

The present invention relates to a pharmaceutical composition containing blood cells or haemopoietic cells, e.g. red blood cells (erythrocytes), granulocytes, mononuclear cells (PBMCs) and/or blood platelets, in combination with a pharmaceutically acceptable excipient and/or vehicle, wherein the cells are transfected with at least one mRNA comprising at least one region coding for at least one antigen. The invention further discloses a method of preparing the aforesaid pharmaceutical composition and the use of blood cells transfected in this way for the preparation of drugs or pharmaceutical compositions for immune stimulation against the antigens encoded by the mRNA. The subjects according to the invention are used especially for the therapy and/or prophylaxis of carcinoses or infectious diseases and can also be employed in gene therapy.

The present invention relates to novel modified proteins having N-terminal free thiols that can be produced by recombinant methods and are ready for further chemical derivatization. In particular, the invention relates to erythropoietin conjugate compounds having altered biochemical, physiochemical and pharmacokinetic properties. More particularly, one embodiment of the invention relates to erythropoietin conjugate compounds of the formula:

(M)_n-X-A-cys-EPO   (I)

where EPO is an erythropoeitin moiety selected from erythropoietin or an erythropoietin variant having at least one amino acid different from the wild-type human EPO, or any pharmaceutical acceptable derivatives thereof having biological properties of causing bone marrow cells to increase production of red blood cells; cys represents the amino acid cysteine and occurs at position −1 relative to the amino acid sequence of the erythropoietin moiety; A indicates the structure of the residual moiety used to chemically attach X to the thiol group of −1Cys; X is a water soluble polymer such as a polyalkylene glycol or other polymer; M is an organic molecule (including peptides and proteins) that increases the circulating half-life of the construct; and N is an integer from 0 to 15.

An automatic method for analyzing nucleated bone marrow cells comprising partitioning one sample of bone marrow fluid with two samples, one sample being treated with a first lysing agent and a first staining solution and the other sample being treated with a second lysing agent and a second staining solution; and measuring each samples in a flow cytometer using a scattered light and fluoresence which enables to classify and count leukocytes, erythroid cells and lipid particles, as well as mature myeloid cells, lymphoid cells and immature myeloid cells, and to calculate the number of myeloid cells as well as the ratio of myeloid cells and erythroid cells.

Antibodies and fragments thereof which activate an erythropoietin receptor and stimulate erythropoiesis are described. Also described are hybridoma cell lines which produce the antibodies and methods and compositions for the treatment of anemia.

The present invention is directed to novel tissue protective peptides. The tissue protective peptides of the invention may bind to a tissue protective receptor complex. In particular, the present invention is drawn to tissue protective peptides derived from or sharing consensus sequences with portions of cytokine receptor ligands, including Erythropoietin (EPO), that are not involved in the binding of the ligand to the receptor complex, e.g., to the EPO receptor homodimer. Accordingly, the tissue protective peptides of the invention are derived from the amino acid sequences of regions of cytokine receptor ligands that are generally located on or within the region of the ligand protein that is opposite of the receptor complex, i.e., are generally derived from amino acid sequences of regions of the ligand protein that face away from the receptor complex while the ligand is bound to the receptor. The invention is further directed to the consensus sequences for use in engineering a synthetic tissue protective peptide. These tissue protective peptides also include fragments, chimeras, as well as peptides designed to mimic the spatial localization of key amino acid residues within the tissue protective receptor ligands, e.g., EPO. The invention further encompasses methods for treating or preventing a disease or disorder using tissue protective peptides of the current invention. The invention also encompasses methods for enhancing excitable tissue function using tissue protective peptides of the current invention.

The present invention relates to the use of erythropoietin for the treatment of disturbances of iron distribution in heart diseases.

A method of, and pharmaceutical composition for, treating disturbances of iron distribution in diabetes using erythropoietin are disclosed.

The present invention relates to new polynucleotides deriving from the nucleotide sequence of the EPO gene and comprising new SNPs, new polypeptides derived from the natural EPO protein and comprising at least one mutation caused by the SNPs of the invention as well as their therapeutic uses.

The invention provides a method for preserving the activity of a human cell membrane blood group antigen, which comprises the steps of: preparing an erythrocyte membrane blood group antigen extract, and then coating the prepared erythrocyte membrane blood group antigen on a solid microsphere so as to replace a fresh erythrocyte to be used for detecting a blood group antibody in a sample.

The present invention relates to a composite microsphere system comprising poly(D,L-lactide-co-glycolide) (PLGA), poly(acryloyl hydroxyethyl starch) (AcHES), and a pharmaceutically effective amount of a biologically active compound. The active compound may be, for example, an insulin, an interferon, a luteinizing hormone-releasing hormone (LHRH) analog, a somatostatin and/or derivatives thereof, a calicitonin, a parathyroid hormone (PTH), a bone morphogenic protein (BMP), an erythropoietin (EPO), an epidermal growth factor (EGF) or a growth hormone. This invention also relates to methods of using the composite microspheres, and methods of preparing same.

Use of a composition comprising a compound of any of formulae I, II, Ila, III and Illa; or a combination thereof wherein each R₁ is independently C_7-11 alkyl; A and B are independently H or CO—R₁; R₂ is H or C_1-4 alkyl; M is a metal monocation (k=1) or dication (k=2); Y is 0 or NH; and Z is 0, NH, CH₂O or a bond; for the manufacture of a medicament for stimulating erythropoiesis. Preferably, the composition further comprises human erythroporietin.

An immunoassay comprises the steps of: (a) mixing a whole blood sample with sensitized insoluble carrier particles smaller than erythrocytes to cause an immune agglutination reaction; (b) introducing the resulting immune agglutination reaction mixture including agglutinated particles and unagglutinated particles to a flow cell, irradiating the particles passing through the flow cell with laser light, and detecting scattered lights generated thereby; (c) setting a threshold value for distinguishing unagglutinated particles from agglutinated particles and a threshold value for distinguishing the agglutinated particles from blood cells with regard to intensity of the scattered light; and (d) distinguishing and counting the unagglutinated particles, the agglutinated particles and the blood cells from the scattered lights detected in the step (b), in reference to the threshold values set in the step (c).

The invention relates to the identification of epitopes for T-cells in human EPO as well as T-cell epitope peptides derived from EPO by means of which it is possible to create novel modified EPO variants with reduced immunogenicity.

The invention discloses a hybridization tumor cell stem 2E8Z CGMCC NO.1942 and monoclonal antibody of human red blood cell surface H antigen thereof. The monoclonal antibody 2E8 of human red blood cell surface H antigen genereated by hybridization tumor cell stem has advantages of high effect, strong differentia, extensive distribution of antigen. The flexible peptide is easy to be bended, so mixed albumen of the invnetion is feld correctly and without influence each activity combination area of the mixed albumen. Experiment evidence, the mixed albumen can specially combine with human red blood cell surface H antigen; moreover, the mixed albumen with high expression amount, easy to be purified, short production cycle, large production scale and low cost. Base on these advantages, the invention plans to use gene engineering method to produce double function molecule and establish good base of treating based on red blood cell and testing platform, having more actual sense and wider application foreground in medical testing field.

The invention discloses a slow-release microsphere preparation containing a recombined human haemopoietin. The slow-release microsphere preparation is prepared by the S/O/W compound emulsion solvent volatilization method. The preparation method comprises that: firstly, by the freeze-drying method, a micro particle containing the human serum albumin and the recombined human haemopoietin is prepared; secondly, by using a biodegradable high molecular material of lactic acid-glycollic acid block copolymer as a carrier material, the micro particle containing the human serum albumin and the recombined human haemopoietin is encapsulated; and thirdly, the lactic acid-glycollic acid block copolymer slow-release microsphere preparation containing the recombined human haemopoietin is prepared. The microsphere of the invention has the advantages of smooth surface, uniform appearance, regular size and no adhesion, the average particle size is between 70 and 105mu m; moreover, the microsphere is high in drug-carrying quantity and encapsulating rate, and the in vitro slow release period is more than 30 days. The obtained slow-release microsphere preparation is good in biocompatibility and can be used for non-intravenous drug administration such as hypodermic drug administration and intramuscular drug administration, and when used as a drug preparation for treating renal anemia, the slow-release microsphere preparation can improve the hematocrit of a patient.

The invention discloses application of erythropoietin microspheres to preparation of drugs for treating motor complications in the Parkinson's disease. The erythropoietin microspheres are obtained by means of preparing one of naturally extracted erythropoietin, genetic recombination expression erythropoietin, polyethylene glycol modified erythropoietin, glycosylation modified erythropoietin or human serum fused erythropoietin with polysaccharides into particles, and preparing the particles with sustained-release materials into the microspheres. The application has the advantages that a novel medicinal use of the erythropoietin microspheres is cultivated, a novel application field is developed, treating and preventing the motor complications in the Parkinson's disease by the erythropoietin microspheres have the advantages of long-acting sustained release, no toxic and side effects, fine compliance, patient pain relieving, low cost and the like and are easily accepted by patients, and the erythropoietin microspheres are simple in preparation process and environment-friendly and have excellent application prospects in treating and preventing the motor complications in the Parkinson's disease.

Methods and compositions of erythroid cells that produce adult β-hemoglobin, generated by culturing CD31+, CD31+/CD34+ or CD34+ cells from embryonic stem cells under serum-free culture conditions.

Methods and uses are provided for a pharmaceutical composition with an erythropoietin or a tissue protective cytokine for protecting or restoring function to a responsive cell, tissue, organ or body part function or viability in mammals when administered outside of the therapeutic window of previously approved therapeutics.

A method for indentifying red cell fragments is used for blood cell analysis with cell counting by the resistance method, and comprises the following steps: A. counting white blood cells in a blood sample, drawing a white blood cell column diagram, and recording the full width at half maximum of each particle pulse during the process of particle pulse signal identification; B. locating an area A with possible existence of red cell fragments and an area B without any red cell fragments on the white blood cell column diagram, and determining whether the existence of red cell fragments interfering with white blood cell counting is true in the area A according to the comparison between the distribution of the full width at half maximum of particle pulse in the area A and in the area B; and C. in the case of disturbance caused by red cell fragments, determining the position, in which the interference peak of red cells ends, and correcting the count value of white blood cells according to the ending position of the interference peak of the red cells. The method achieves the effect of improving the accuracy of the result of white blood cell counting and the accuracy of white blood cell classification.